- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: ChAglyCD3 | TRX4
Compound class: Antibody
Comment: Otelixizumab is a chimeric humanized IgG1 monoclonal antibody targeting the CD3E component of the T cell receptor. The antibody is aglycosylated. Otelixizumab was investigated as a potential treatment for autoimmune diseases including type I diabetes [3-4].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
|Although peptide sequences for otelixizumab match sequences covered by patents such as US5585097 and US7993641, these do not provide affinity data for the interaction between the antibody and CD3E. We have tagged the primary molecular target based on experimental data contained within the patents and on Bolt et al.'s 1993 article describing development of the antibody .|
|Selectivity at other protein targets|
|Key to terms and symbols||Click column headers to sort|